referred to tuberculosis clinics, only 11% started ART within 4 weeks after receiving a diagnosis of tuberculosis. This is a prime example of how a lack of integration of tuberculosis and ART services compromises patient care. Progress toward integration is slow and must be accelerated. The time between tuberculosis diagnosis and initiation of ART might be a useful indicator of successful integration.
Stephen D. Lawn, M.D.
To the Editor: Török and Farrar 1 summarize the findings of three controlled trials of when to start ART in HIV-associated tuberculosis and raise a number of practical issues to consider outside of the research setting. A practical point not considered is the setting of ART initiation. Loss to follow-up is typically the largest contrib- utor to attrition from HIV care, 2 and initiating ART in patients in the hospital is associated with a doubling of the risk of loss to follow-up as compared with initiating ART in patients who are not in the hospital. 3 Inpatient ART initiation will be necessary in severely immunocompromised patients or those with long hospital stays, in which case adequate linkage to community programs must be ensured. Studies show that ART can safely be delayed in less severely immunocompromised patients with the possible advantages of reduced risks of immune reconstitution inflammatory syndrome (IRIS) and adverse events leading to switches in antiretroviral drugs.
Outpatient ART initiation should be the preferred option whenever possible. Adequate linkage to outpatient care allowing prompt ART initiation in the community will also be important in securing the success of this approach. Tom H. Boyles, B.M., B.Ch.
University of Cape Town Cape Town, South Africa tomboyles@yahoo.com
No potential conflict of interest relevant to this letter was reported. 
Dr. Blanc and coauthors Reply: Lawn and
Wood point out that a major hurdle to rapidly initiating ART in patients with HIV-associated tuberculosis is the separation between tuberculosis and HIV services that is typical of most resource-limited settings. We cannot agree more. On the basis of the results of the Cambodian Early versus Late Introduction of Antiretrovirals trial (CAMELIA; ClinicalTrials.gov number, NCT00226434) and two other recent studies, which show that early initiation of ART in very immunosuppressed patients with tuberculosis decreases mortality, it is no longer acceptable to allow patients to wait for treatment while being referred from tuberculosis services to HIV services or vice versa. In these patients, tuberculosis treatment and ART should be initiated at the same place to save time and to ultimately save lives. Therefore, to reduce the interval between the start of treatment for each of the two infections, we urge early initiation of ART in tuberculosis services and an expedited process for patients to receive tuberculosis treatment in HIV services. We anticipate that this strategy, which was successfully accomplished in Cambodia during the CAMELIA trial, will have a considerable impact on the mortality associated with tuberculosis and HIV coinfection. 
Dr. Havlir and coauthors Reply:
Delivering antiretroviral therapy as early as 2 weeks after a tuberculosis diagnosis will require major adaptations in health delivery for patients with HIV and tuberculosis. As reported by Lawn and Wood, inadequate integration of HIV and tuberculosis services leads to delays in antiretroviral initiation and excess mortality. 1 Several models to deliver integrated care are emerging and include "partial integration," in which tuberculosis clinics manage antiretroviral therapy during tuberculosis treatment and "co-location" of HIV and tuberculosis clinics. With any model, streamlined HIV counseling, provider education including management of the IRIS, and rigorous infection-control policies to reduce transmission of tuberculosis are essential components. 2 Integration of some HIV and tuberculosis activities such as HIV testing among tuberculosis patients has increased over the past few years. 3 New data from our study and others call for acceleration of the integration of HIV and tuberculosis services and early delivery of HIV antiretroviral therapy to reduce mortality and AIDS among HIV-infected patients who acquire tuberculosis. 
